RNXT: RenovoRx, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
28 institutions reported holding $9.00M of RenovoRx, Inc. on Form 13F (31 the quarter before). 3 opened a new position and 6 sold out. Shares held by institutions: +8%.
| Largest holders | Shares | Value |
|---|---|---|
| AIGH Capital Management LLC | 4,405,439 | $4.32M |
| Bleichroeder LP | 1,666,098 | $1.63M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,443,742 | $1.41M |
| GEODE CAPITAL MANAGEMENT, LLC | 424,148 | $416K |
| Wealthspire Advisors, LLC | 252,525 | $247K |
| VANGUARD FIDUCIARY TRUST CO | 240,330 | $236K |
| CITADEL ADVISORS LLC | 133,597 | $131K |
| NORTHERN TRUST CORP | 85,207 | $84K |
| Chicago Partners Investment Group LLC | 92,356 | $79K |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 74,596 | $73K |
Clinical trial readouts
1 Phase 2 or 3 trials by RenovoRx, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-06 (est.) | RenovoCath | Locally Advanced Pancreatic Cancer | Phase 3 | 190 | Enrollment complete | NCT03257033 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.